Graft cell selection to prevent GVHD in children with non-cancer diseases
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests if removing a type of immune cell from a donor's stem cell graft can prevent graft-versus-host disease (GVHD) in children with certain non-cancer blood or immune disorders. It aims to make the transplant safer by reducing the risk of the donor cells attacking the child's body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 6 months and 5 years old.
- Your child has a non-cancer disease like bone marrow failure, sickle cell disease, immune deficiency, or other similar conditions that can be treated with a stem cell transplant.
- Your child has a suitable donor (such as a matched family member or unrelated donor).
- Your child does not have aplastic anemia, severe combined immunodeficiency, Fanconi anemia, or dyskeratosis congenita.
- Your child does not have uncontrolled infections, organ problems (kidney, heart, lung, liver), or current cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding back certain immune cells after a stem cell transplant can help prevent serious viral or fungal infections. It's for children and young adults up to age 25 who need a transplant for a blood cancer or other curable disease.
This trial tests whether removing certain immune cells (T cells) from the donor transplant can lower the risk of chronic graft-versus-host disease (long-term immune attack after transplant) in children and young adults with blood cancers. If you qualify, it may help improve transplant outcomes while tracking safety and side effects.
This trial tests a combination of four medicines (cyclophosphamide, abatacept, vedolizumab, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant for children and young adults with certain blood cancers. The goal is to see if this approach reduces the risk of GVHD, a serious complication where donor cells attack the body.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
Hear when a new Bone Marrow Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.